This article is more than 5 years old. Information may no longer be current.

Stopping anticoagulation therapy unnecessary before vitreoretinal surgery, study suggests

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Stopping systemic use of the anticoagulation drug warfarin may not be necessary before vitreoretinal surgery, according to a study by researchers in California. Most patients receiving treatment with the drug underwent successful vitreoretinal procedures without complications, the authors noted.

Arthur D. Fu, MD, of the California Pacific Medical Center, San Francisco, and colleagues reviewed outcomes for 25 patients who underwent vitreoretinal surgery while using warfarin. At 19.5 months mean follow-up, visual acuity ranged from 20/20 to 20/400, according to the study.

Only one patient experienced a complication, the authors noted. This patient experienced a subretinal hemorrhage, which occurred as surgeons drained subretinal fluid and was associated with the drainage device, the authors said.

The study is published in the March issue of Retina.